An Open, Randomized, Multi-centre Investigation With Mepilex Ag Versus Silver Sulfadiazine in the Treatment of Deep Partial Thickness Burn Injuries.

Inclusion Criteria:

• Subjects with a deep partial-thickness burn injury covering 2.5%-25% TBSA (3rd degree areas not to exceed 10% TBSA)
• Burn of thermal origin
• Both gender with an age ≥5 years and ≤65 years at ICF
• Understood and signed informed consent
• Subjects who are younger than the legal consenting age must have a legally authorized representative

One study burn should be chosen which fulfil the following criteria;

1. isolated burn area (not head and/or face)
2. 2nd degree deep partial
3. area is from 1 to 10% BSA

All deep 2nd degree burn should be treated with the investigation product, Mepilex Ag/SSD (according to the randomization).

Exclusion Criteria:

• Burns "occurred" equal to or older than 36 hours
• Burns of chemical and electrical origin
• Clinically infected burn (as judged by the investigator)
• Subjects with lung injury or subjects being on a ventilator
• Treatment of the burn with an active agent before study entry. SSD is allowed up to 24 hours prior to randomization
• Subjects with dermatologic skin disorders or necrotizing processes
• Diagnosed underlying disease(s) (e.g. HIV/AIDS, cancer and severe anaemia) judged by the investigator to be a potential interference in the treatment
• Subjects with insulin dependent diabetes mellitus
• Subjects treated with systemic glucocorticosteroids, except Subjects taking occasional doses or doses less than 10mg prednisolon (day or equivalent
• Use of immunosuppressive agents, radiation or chemotherapy within the past 30 days
• Known allergy/hypersensitivity to any of the components (SSD , Ag glycerin, monostearate, glycerol, cetearyl alcohol, leveling agent O, albolene, light liquid paraffin, ethylparaben/ silicone, polyurethane foam pad containing a silver compound, activated carbon)of the investigation products
• Subjects with physical and/or mental conditions that are not expected to comply with the investigation
• Participation in other clinical investigation(s) within 1 month prior to start of the investigation
• Pregnancy (pregnancy test needed if they do not use contraceptive)
• Previously randomized to this investigation (PUMA 418